Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
UNIVERSITAT DE GIRONA manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The current prosecution status involves 1 pending office action. This specific matter represents the full scope of the company's active engagement with the patent office at this time. The resolution of this 1 pending office action will define the portfolio's immediate progress.
The company's strategy is concentrated within 1 distinct examiner and 1 distinct art unit. This level of focus suggests that the legal team can dedicate its attention to the specific procedural requirements of an individual technical group. Because only 1 distinct art unit is involved, there is no need to coordinate across different examination divisions. The presence of 1 distinct examiner ensures that the company receives feedback from a consistent point of authority.
GIAMMONA, FRANCESCA FILIPPA is the busiest examiner for this portfolio, currently handling 1 busiest examiner pending office action. The outcome of the company's current efforts in Biotechnology & Pharmaceuticals depends on the resolution of this specific case. Practitioners should prepare for the 1 busiest examiner pending office action by reviewing the previous rulings and preferences of GIAMMONA, FRANCESCA FILIPPA.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GIAMMONA, FRANCESCA FILIPPA | 1 | 37.5% | +57.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17438173 | IMPROVED METHOD FOR THE SCREENING, DIAGNOSIS AND/OR MONITORING OF COLORECTAL ADVANCED NEOPLASIA, ADVANCED ADENOMA AND/OR COLORECTAL CANCER | GIAMMONA, FRANCESCA FILIPPA | 70d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17438173 | IMPROVED METHOD FOR THE SCREENING, DIAGNOSIS AND/OR MONITORING OF COLORECTAL ADVANCED NEOPLASIA, ADVANCED ADENOMA AND/OR COLORECTAL CANCER | GIAMMONA, FRANCESCA FILIPPA | 70d |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17438173 | IMPROVED METHOD FOR THE SCREENING, DIAGNOSIS AND/OR MONITORING OF COLORECTAL ADVANCED NEOPLASIA, ADVANCED ADENOMA AND/OR COLORECTAL CANCER | GIAMMONA, FRANCESCA FILIPPA | 1681 | §103§112 | Final Rejection | 70d | Pending | Sep 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial